Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approach

Alzheimer's and Dementia

Volumn 12, Issue 10, 2016, Pages 1098-1107

  Shamir, Dov B ^a   Rosenqvist, Nina ^b   Rasool, Suhail ^a   Pedersen, Jan T ^b   Sigurdsson, Einar M ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b H LUNDBECK A S   (Denmark)

Author keywords

Alzheimer's disease; Antibody; Flow cytometry; Immunotherapy; Internalization; Neuroblastoma cells; Paired helical filaments; SH SY5Y cells; Tau protein; Uptake

Indexed keywords

PROTEIN ANTIBODY; TAU PROTEIN; TAU PROTEIN ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY;

ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; NEUROBLASTOMA CELL; NEUROBLASTOMA CELL LINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TRANSPORT; WESTERN BLOTTING; ALZHEIMER DISEASE; ANIMAL; BRAIN; METABOLISM; NERVE CELL; NEUROFIBRILLARY TANGLE; PATHOLOGY; PHOSPHORYLATION; PROCEDURES;

ALZHEIMER DISEASE; ANIMALS; ANTIBODIES; BLOTTING, WESTERN; BRAIN; FLOW CYTOMETRY; HUMANS; NEUROFIBRILLARY TANGLES; NEURONS; PHOSPHORYLATION; TAU PROTEINS;

EID: 84995526738     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.01.013     Document Type: Article

References (44)

1. [1] Pedersen, J.T., Sigurdsson, E.M., Tau immunotherapy for Alzheimer's disease. Trends Mol Med 21 (2015), 394–402.
2. [2] Spencer, B., Masliah, E., Immunotherapy for Alzheimer's disease: past, present and future. Front Aging Neurosci, 6, 2014, 114.
3. [3] Yu, Y.J., Watts, R.J., Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics 10 (2013), 459–472.
4. [4] Asuni, A.A., Boutajangout, A., Quartermain, D., Sigurdsson, E.M., Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27 (2007), 9115–9129.
5. [5] Boutajangout, A., Ingadottir, J., Davies, P., Sigurdsson, E.M., Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 118 (2011), 658–667.
6. [6] Boutajangout, A., Quartermain, D., Sigurdsson, E.M., Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 30 (2010), 16559–16566.
7. [7] Boimel, M., Grigoriadis, N., Lourbopoulos, A., Haber, E., Abramsky, O., Rosenmann, H., Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 224 (2010), 472–485.
8. [8] Chai, X., Wu, S., Murray, T.K., Kinley, R., Cella, C.V., Sims, H., et al. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem 286 (2011), 34457–34467.
9. [9] Bi, M., Ittner, A., Ke, Y.D., Gotz, J., Ittner, L.M., Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice. PLoS One, 6, 2011, e26860.
10. [10] Troquier, L., Caillierez, M., Burnouf, S., Fernandez-Gomez, F.J., Grosjean, M.J., Zommer, N., et al. Targeting phospho-Ser422 by active Tau immunotherapy in the THY-Tau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 9 (2012), 397–405.
11. [11] Kfoury, N., Holmes, B.B., Jiang, H., Holtzman, D.M., Diamond, M.I., Trans-cellular Propagation of Tau Aggregation by Fibrillar Species. J Biol Chem 287 (2012), 19440–19451.
12. [12] d'Abramo, C., Acker, C.M., Jimenez, H.T., Davies, P., Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity. PLoS One, 8, 2013, e62402.
13. [13] Congdon, E.E., Gu, J., Sait, H.B., Sigurdsson, E.M., Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fcgamma Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance. J Biol Chem 288 (2013), 35452–35465.
14. [14] Gu, J., Congdon, E.E., Sigurdsson, E.M., Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology. J Biol Chem 288 (2013), 33081–33095.
15. [15] Theunis, C., Crespo-Biel, N., Gafner, V., Pihlgren, M., Lopez-Deber, M.P., Reis, P., et al. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS One, 8, 2013, e72301.
16. [16] Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T.E., Ma, S., Maloney, S.E., et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80 (2013), 402–414.
17. [17] Castillo-Carranza, D.L., Gerson, J.E., Sengupta, U., Guerrero-Munoz, M.J., Lasagna-Reeves, C.A., Kayed, R., Specific targeting of tau oligomers in htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. J Alzheimers Dis 40 (2014), S97–S111.
18. [18] Castillo-Carranza, D.L., Sengupta, U., Guerrero-Munoz, M.J., Lasagna-Reeves, C.A., Gerson, J.E., Singh, G., et al. Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles. J Neurosci 34 (2014), 4260–4272.
19. [19] Walls, K.C., Ager, R.R., Vasilevko, V., Cheng, D., Medeiros, R., LaFerla, F.M., p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice. Neurosci Lett 575 (2014), 96–100.
20. [20] Kontsekova, E., Zilka, N., Kovacech, B., Novak, P., Novak, M., First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res Ther, 6, 2014, 44.
21. [21] Collin, L., Bohrmann, B., Gopfert, U., Oroszlan-Szovik, K., Ozmen, L., Gruninger, F., Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease. Brain 137 (2014), 2834–2846.
22. [22] Selenica, M.L., Davtyan, H., Housley, S.B., Blair, L.J., Gillies, A., Nordhues, B.A., et al. Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis. J Neuroinflammation, 11, 2014, 152.
23. [23] Ittner, A., Bertz, J., Suh, L.S., Stevens, C.H., Gotz, J., Ittner, L.M., Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice. J Neurochem 132 (2015), 135–145.
24. [24] Umeda, T., Eguchi, H., Kunori, Y., Matsumoto, Y., Taniguchi, T., Mori, H., et al. Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice. Ann Clin Transl Neurol 2 (2015), 241–255.
25. [25] d'Abramo, C., Acker, C.M., Jimenez, H., Davies, P., Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies. PLoS One, 10, 2015, e0135774.
26. [26] Bright, J., Hussain, S., Dang, V., Wright, S., Cooper, B., Byun, T., et al. Human secreted tau increases amyloid-beta production. Neurobiol Aging 36 (2015), 693–709.
27. [27] Sankaranarayanan, S., Barten, D.M., Vana, L., Devidze, N., Yang, L., Cadelina, G., et al. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. PLoS One, 10, 2015, e0125614.
28. [28] Kondo, A., Shahpasand, K., Mannix, R., Qiu, J., Moncaster, J., Chen, C.H., et al. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature 523 (2015), 431–436.
29. [29] Yanamandra, K., Jiang, H., Mahan, T.E., Maloney, S.E., Wozniak, D.F., Diamond, M.I., et al. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol 2 (2015), 278–288.
30. [30] Funk, K.E., Mirbaha, H., Jiang, H., Holtzman, D.M., Diamond, M.I., Distinct therapeutic mechanisms of tau antibodies: Promoting microglial clearance versus blocking neuronal uptake. J Biol Chem 290 (2015), 21652–21662.
31. [31] Schroeder, S.K., Joly-Amado, A., Gordon, M.N., Morgan, D., Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies. J Neuroimmune Pharmacol 11 (2016), 9–25.
32. [32] Castillo-Carranza, D.L., Guerrero-Munoz, M.J., Sengupta, U., Hernandez, C., Barrett, A.D., Dineley, K., et al. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model. J Neurosci 35 (2015), 4857–4868.
33. [33] Dai, C.L., Chen, X., Kazim, S.F., Liu, F., Gong, C.X., Grundke-Iqbal, I., et al. Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. J Neural Transm (Vienna) 122 (2015), 607–617.
34. [34] Krishnamurthy, P.K., Deng, Y., Sigurdsson, E.M., Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model. Front Psychiatry, 2, 2011, 59.
35. [35] Krishnaswamy, S., Lin, Y., Rajamohamedsait, W.J., Rajamohamedsait, H.B., Krishnamurthy, P.K., Sigurdsson, E.M., Antibody derived in vivo imaging of tau pathology. J Neurosci 34 (2014), 16835–16850.
36. [36] Shamir, D.B., Rosenqvist, N., Rasool, S., Pedersen, J.T., Sigurdsson, E.M., Uptake of tau antibodies into PHF-pretreated transfected human neuroblastoma cells leads to a decrease in tau protein levels. Alzheimers Dement, 10, 2014, P647.
37. [37] Shamir, D.B., Rosenqvist, N., Gregory, M.D., Rasool, S., Pedersen, J.T., Sigurdsson, E.M., Uptake of tau antibodies and paired helical filament enriched tau protein in naive and transfected human neuroblastoma cells. Soc Neurosci Abstr, 2013 524.05/H21.
38. [38] Holmes, B.B., Furman, J.L., Mahan, T.E., Yamasaki, T.R., Mirbaha, H., Eades, W.C., et al. Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci U S A 111 (2014), E4376–E4385.
39. [39] Santa-Maria, I., Varghese, M., Ksiezak-Reding, H., Dzhun, A., Wang, J., Pasinetti, G.M., Paired helical filaments from Alzheimer disease brain induce intracellular accumulation of Tau protein in aggresomes. J Biol Chem 287 (2012), 20522–20533.
40. [40] Walker, L.C., Diamond, M.I., Duff, K.E., Hyman, B.T., Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol 70 (2013), 304–310.
41. [41] Frost, B., Jacks, R.L., Diamond, M.I., Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284 (2009), 12845–12852.
42. [42] Falcon, B., Cavallini, A., Angers, R., Glover, S., Murray, T.K., Barnham, L., et al. Conformation determines the seeding potencies of native and recombinant Tau aggregates. J Biol Chem 290 (2015), 1049–1065.
43. [43] Wu, J.W., Herman, M., Liu, L., Simoes, S., Acker, C.M., Figueroa, H., et al. Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem 288 (2013), 1856–1870.
44. [44] Shamir, D.B., Sigurdsson, E.M., Tau antibodies reduce tau levels in differentiated but not in non-differentiated human SH-SY5Y cells. Soc Neurosci Abstr, 2015 579.15/C45.